Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine

Phase 3

Novartis AG (NVS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

12 competitors in Influenza

RHHBYRoche influenza treatment

MRNAmRNA Flu vaccine

SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)

Phase 3

BNTXInfluenza and COVID-19 Combination A

Phase 3

BNTXInvestigational COVID-19 Vaccine

Phase 2

View Full Landscape

Drug Information

Target Indication

Influenza

Clinical Trial

NCT00996138

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Benazepril plus hydrochlorothiazidePhase 3

Hypertension

Verteporfin PDTPhase 3

Pathological Myopia

Certican®Phase 3

Renal Interstitial Fibrosis

lisinoprilPhase 3

Hypertension

[68Ga]Ga-PSMA-11Phase 3

Prostatic Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts